Indian Supreme Court Rejects Trivial 'Evergreening' Of Pharma Patents
Back in October last year, in the context of India showing itself increasingly sceptical about pharma patents that drive up drug prices beyond the reach of its citizens, we wrote about an important court battle over Novartis's drug Gleevec, sold as Glivec in India. The definitive judgement from India's Supreme Court was announced today, reported here by The Guardian:
On Techdirt.
Posts
No comments:
Post a Comment